Juan Manuel O'Connor is an expert in Oncology at Instituto Alexander Fleming (Argentina). As of September 2026, ScienceLeadR ranks Juan Manuel O'Connor in the top 1% of experts in Argentina for Gastrointestinal Neoplasms, Intestinal Neoplasms and Stomach Neoplasms. Juan Manuel O'Connor has authored 87 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 345 (community average: 125). How the SLR is computed.

LeadR Profile

Juan Manuel O'Connor Instituto Alexander Fleming Argentina
345 ScienceLeadR Reputation 345
Network Map

Oncology

Subspecialties: Gastroenterology - Genetics - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026

Source: PubMed

Instituto Alexander Fleming

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 87

Citations

Citations: 2 967 1st author: 9 Last author: 15 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
PMID 42716074 — leucovorin, disease-free survival, docetaxel, adenocarcinoma, oxaliplatin, fluorouracil, therapeutics
Lancet Top journal20261
Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers.
PMID 42295754 — pancreatic neoplasms, carcinoma, hepatocellular, neoplasms, colorectal neoplasms, stomach neoplasms
Expert Rev Anticancer Ther20260
Early-onset colorectal cancer: a comprehensive review reframing hypotheses and defining research priorities.
PMID 42115377 — neoplasms, diagnosis, research, therapeutics, colorectal neoplasms, colorectal surgery
Int J Colorectal Dis20260
Real-world outcomes of lower lenvatinib doses in advanced neuroendocrine tumors: a multinational retrospective study.
PMID 41358254 — safety, retrospective studies, neoplasms, neoplasm metastasis, neuroendocrine tumors, carcinoid tumor, genes, mos
Endocr Oncol20250
[Hyperprogression in a patient with colorectal cancer and repair protein deficiency: a diagnostic and therapeutic challenge].
PMID 41109298 — microsatellite repeats, neoplasms, protein deficiency, immunotherapy, therapeutics, colorectal neoplasms, microsatellite instability, colonic neoplasms, msi-h
Medicina (B Aires)20250

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 6
N/A 1
Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 5
Active not recruiting 3
Unknown 1

By type:

Interventional 8
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 6

Main Topics

LeadR Networks

Main global connection map